UC, Cincinnati Children's to Host 50th Anniversary Celebration of Sabin Sundays
CINCINNATIThe University of Cincinnati and Cincinnati Childrens Hospital Medical Center will team up to remember and celebrate the 50th anniversary of "Sabin Sunday (April 24, 1960), the first day of a campaign to vaccinate children in Cincinnati and Hamilton County using the worlds first oral, live-virus polio vaccine.
Albert Sabin, MD, developed the vaccine while on faculty at the UC College of Medicine and a member of the research staff at Cincinnati Childrens Research Foundation.
The vaccine had been tested in other countries but had no widespread use in the United States before this trial. Within a short time 180,000 local children were vaccinated, and the free distribution of vaccinewhich has come to be known as Sabin Sundaysled to the vaccine being licensed in the U.S. and distributed nationwide. It has since been credited with eradicating polio from most of the world.
A series of distinguished speakers, including Phillip Russell from the Sabin Vaccine Institute in Washington, D.C., and Mark Dine, MD, a pediatrician who administered the vaccine in April 1960, will be on hand to honor Sabins work and this key date in history. Other guests will reflect on Sabins pioneering research and its impact locally and globally, while also highlighting current vaccine research.
The celebration will begin at 2 p.m. Friday, April 23, in the dining area of the CARE/Crawley Building, at the corner of Albert Sabin Way and Eden Avenue on UCs medical campus.
Sabins widow, Heloisa Sabin, will be on hand to celebrate the anniversary with faculty and staff from UC and Cincinnati Childrens. Event-goers will be treated to a light reception and a display of historical artifacts from the era, including an early iron lung used to treat polio patients.
For more information or to RSVP to this event, call (513) 558-4553 or e-mail uchealthnews@uc.edu.
Albert Sabin, MD, administering his vaccine.
Albert Sabin, MD.
Albert Sabin postage stamp
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.